EspanaSalude.Org

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

January 07, 2016

Oral: "DURATION-3: Efficacy of Exenatide Once Weekly (EQW) and Insulin Glargine QD (IG) After 84 Weeks in Patients with Type 2 Diabetes (T2D)" will be presented by Michaela Diamant, M.D. on Monday, June 27 at 9:00 AM PT. Oral: "Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-na??ve Patients with Type 2 Diabetes (DUR-4)" will be presented by David Russell-Jones, M.D. on Monday, June 27 at 9:45 AM PT. Late Breaking Poster: "Safety and Efficacy of Once-Monthly Exenatide Over 20 Weeks in Patients with Type 2 Diabetes" will be presented by Leigh MacConell, Ph.D. during a poster session on Sunday, June 26 from 12:00 ?? 2:00 PM PT. Poster: "Exenatide Once Weekly Did Not Affect Corrected QT Interval in Patients with Type 2 Diabetes" will be presented by Philip Sager, M.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT. Poster: "Exenatide Once Weekly: Sustained Improvement in Glycemic Control and Weight Loss Through 3 Years" will be presented by Leigh MacConell, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT.Poster: "Efficacy and Safety of Exenatide Once Weekly Across Background Therapies: A Pooled Analysis of DURATION Studies" will be presented by James Malone, M.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT.Poster: "The Risk of Heart Failure Among Patients Receiving Exenatide Versus Other Glucose-Lowering Medications for Type 2 Diabetes: A Matched Retrospective Cohort Analysis of the GE Healthcare Electronic Medical Record Database" will be presented by Jennie Best, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT. Poster: "Weight Change in Placebo- and Exenatide (BID)-Treated Subjects with Type 2 Diabetes on Insulin Glargine: Effects of Sex, Diabetes Duration, Baseline A1C, and Insulin Dose" will be presented by John Buse, M.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT.Poster: "Effects of Pramlintide in Patients with T2DM Using Larger Doses of Insulin ?? A Tertile Analysis Based on Daily Insulin Dose" will be presented by Kathrin Herrmann, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT.Poster: "Efficacy and Safety of Adjunctive Subcutaneous Injections of Pramlintide in Patients with Type 1 Diabetes Using Insulin Pumps" will be presented by Kathrin Herrmann, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM ?? 1:30 PM PT.

SOURCE Amylin Pharmaceuticals, Inc.